Nasus Pharma Ltd最新公布的中期试验数据显示，其研发的Ns002在药物吸收速度与峰值血药浓度两项关键指标上均显著优于市场主流产品Epipen。实验结果表明，Ns002能够实现更快速的系统性吸收，同时达到更高的血浆峰值水平，这一特性可能为紧急过敏反应治疗提供更高效的临床解决方案。
Nasus Pharma Ltd最新公布的中期试验数据显示，其研发的Ns002在药物吸收速度与峰值血药浓度两项关键指标上均显著优于市场主流产品Epipen。实验结果表明，Ns002能够实现更快速的系统性吸收，同时达到更高的血浆峰值水平，这一特性可能为紧急过敏反应治疗提供更高效的临床解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.